CTLA4 / IL-2 Reporter - Jurkat Recombinant Cell Line

Catalog #
79525
$11,095 *
Size: 2 vials
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant Jurkat T cell expressing firefly luciferase gene under the control of IL-2 promoter with constitutive expression of human CTLA4 (Cytotoxic T-Lymphocyte Associated Protein, CD152; GenBank Accession #NM_005214).

Interested in screening and profiling inhibitors, blocking antibodies, or activators of CTLA4 without the need to purchase and license the cell line? Check out our Cell Signaling Pathway Screening.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

Synonyms
CD152, ctla4 il2 jurkat, il2, CTLA-4
Product Info
Storage and Usage
Citations
Host Cell Line
Jurkat T
Supplied As
Each vial contains 2 x 106 cells in 1 ml of 10% DMSO
Materials Required But Not Supplied

• Raji cell (ATCC # CCL-86)

Thaw Medium 2 (BPS Bioscience #60184)

Growth Medium 2A (BPS Bioscience #60190)

• Assay medium: RPMI1640 medium (Life Technologies #A10491-01)

Anti-CD3 agonist antibody (BPS Bioscience #71274)

• Anti-CTLA4 neutralizing antibody (Biolegend #349904, clone#L3D10)

• 96-well tissue culture-treated white clear-bottom assay plate

One-Step luciferase assay system (BPS bioscience # 60690) or other luciferase reagents for measuring firefly luciferase activity

• Luminometer

UniProt #
P16410
Mycoplasma Testing

The cell line has been screened using the PCR-based Venor®GeM Mycoplasma Detection kit (Sigma-Aldrich) to confirm the absence of Mycoplasma species.

Background
CTLA4, also known as CD152, is a protein receptor that functioning as an immune checkpoint. It is expressed by activated T cells and transmits an inhibitory signal to T cells. CTLA4 is homologous to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells. CTLA-4 binds to CD80 and CD86 with greater affinity and avidity than CD28 thus enabling it to outcompete CD28 for its ligands and act as an “off” switch when bound to CD80 or CD86. CTLA-4 is an important immunotherapy target for the treatment of cancer and autoimmune diseases.